Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes

Next Previous
Search
Trial Profile

Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms STEP 2
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 24 Jun 2023 Results of pooled analysis from STEP 1 and STEP 2 presented at the European Association for the Study of the Liver Congress 2023
    • 01 Dec 2022 Results assessing the safety and efficacy of a weekly 2.4-mg subcutaneous injection of semaglutide for chronic weight management in STEPS 1-4 studies, published in the American Journal of Managed Care.
    • 23 Sep 2022 Results assessing the relationship between body weight loss and glycaemiccontrol in participants with overweight/obesity and T2D receiving semag-lutide pharmacotherapy, esented at the 58th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top